Investor Presentaiton

CSL Seqirus Revenue up 2%¹ Revenue $m Change1% Egg Based 123 0% Cell Culture 529 (13%) Adjuvanted Egg 988 14% In License Pandemic Other Income Total Current Season Dynamics • Reduced rates of immunisation Competitive price pressures Overburdened healthcare system Performance Revenue growth in the northern hemisphere influenza market in a challenging season Heightened recognition of benefits of differentiated product portfolio Continued FLUADⓇ preferential recommendation in the UK First season following US ACIP preferred recommendation for FLUADⓇ in 65+ Major Brands INFLUENZA VACCINE afluria QUADRIVALENT Influenza Vaccine FLUCELVAX. QUADRIVALENT FLUAD 65 65 (23%) Transition to single dose Gardasil vaccine program 85 9% 14 67% 1,804 2% 1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail. 7 Driven by Our Promise CSL

View entire presentation